Helen Schneider Hospital for Women, Rabin Medical Center, Petah-Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Inflamm Bowel Dis. 2023 Jul 5;29(7):1098-1104. doi: 10.1093/ibd/izac185.
Pregnant patients with inflammatory bowel diseases (IBDs) are frequently treated with immunomodulatory agents and may be at increased risk of adverse outcomes, including peripartum infections. We sought to examine the risk for peripartum infections in patients with IBD compared with control subjects and identify potential risk factors associated with peripartum infections in these patients.
This retrospective cohort study compared peripartum infection rates and associated risk factors between pregnant women with and without IBD. The study population included women attending a dedicated joint maternal-fetal medicine and gastroenterology clinic for pregnant women with IBD between 2012 and 2019 at the Rabin Medical Center in Israel, a major referral center for patients with IBD. For each patient, 5 women without IBD were matched according to the newborn's birth date (±2 years), age, parity, and body mass index. Peripartum infection was defined as any 1 of the following: chorioamnionitis, maternal fever (>38°C) detected during labor or postpartum hospitalization, and positive culture taken during the hospitalization.
Overall, 195 pregnant women with IBD (72 [37%] with ulcerative colitis, 123 [63%] with Crohn's disease) were matched with 888 control subjects. The mean disease duration was 8.4 ± 7.02 years. IBD therapy, used by 81%, included most frequently 5-aminosalicylic acid (44%) and tumor necrosis factor inhibitors (27%). Peripartum infections were observed in 15 (7.7%) patients and 49 (5.5%) control subjects (P = 1.00). No medication significantly increased the likelihood of peripartum infection. Cesarean delivery was more likely among women with IBD but was not associated with an increased risk of peripartum infection.
Peripartum infections were comparable in patients with IBD and control subjects. These reassuring data augment existing knowledge of obstetrical outcomes in IBD patients and contribute to the discussion between caregivers and patients.
患有炎症性肠病(IBD)的孕妇常接受免疫调节剂治疗,发生围产期感染的风险可能增加,包括围产期感染。我们旨在研究 IBD 患者与对照人群相比,围产期感染的风险,并确定这些患者发生围产期感染的潜在危险因素。
这项回顾性队列研究比较了 2012 年至 2019 年在以色列拉宾医疗中心有 IBD 的孕妇专用母胎医学和胃肠病学诊所就诊的孕妇中 IBD 患者与无 IBD 患者的围产期感染率及相关危险因素。为每位患者匹配了 5 名无 IBD 的孕妇,匹配依据为新生儿出生日期(±2 年)、年龄、产次和体重指数。围产期感染定义为以下任何一种情况:绒毛膜羊膜炎、产时或产后住院期间母亲发热(>38°C)和住院期间阳性培养。
总体而言,195 名患有 IBD 的孕妇(72 名患有溃疡性结肠炎,63%患有克罗恩病)与 888 名对照者相匹配。平均疾病持续时间为 8.4±7.02 年。81%的患者接受 IBD 治疗,最常用的药物为 5-氨基水杨酸(44%)和肿瘤坏死因子抑制剂(27%)。15 名(7.7%)患者和 49 名(5.5%)对照者发生围产期感染(P=1.00)。没有药物显著增加围产期感染的可能性。IBD 患者行剖宫产的可能性更大,但与围产期感染风险增加无关。
IBD 患者与对照者的围产期感染率相当。这些令人安心的数据增加了对 IBD 患者产科结局的现有认识,并有助于护理人员与患者之间的讨论。